Cipla Ltd
NSE: CIPLA BSE: 500087
Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs[1]
₹1,434
52W: ₹1166 — ₹1673
PE 31.3 · Book ₹423 · +239% vs bookMarket Cap₹1,15,855 Cr
Stock P/E31.3Price to Earnings
ROCE14.7%Return on Capital
ROE11.2%Return on Equity
Div. Yield0.92%Face Value ₹2
Strengths
- +Company is almost debt free.
- +Company has been maintaining a healthy dividend payout of 26.9%
Weaknesses
- −The company has delivered a poor sales growth of 10.9% over past five years.
- −Promoter holding has decreased over last 3 years: -4.34%
Shareholding Pattern
Promoters29.22%
FIIs22.55%
DIIs31.71%
Public16.26%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 30.91% | 30.93%▲0.0 | 29.19%▼1.7 | 29.2%▲0.0 | 29.19%▼0.0 | 29.22%▲0.0 | 29.22% | 29.22% |
| FIIs | 27.82% | 28.8%▲1.0 | 26.65%▼2.2 | 26.28%▼0.4 | 25.24%▼1.0 | 24.54%▼0.7 | 23.93%▼0.6 | 22.55%▼1.4 |
| DIIs | 24.66% | 23.95%▼0.7 | 27.49%▲3.5 | 27.89%▲0.4 | 28.98%▲1.1 | 29.98%▲1.0 | 30.45%▲0.5 | 31.71%▲1.3 |
| Public | 16.4% | 16.11%▼0.3 | 16.43%▲0.3 | 16.36%▼0.1 | 16.3%▼0.1 | 15.99%▼0.3 | 16.12%▲0.1 | 16.26%▲0.1 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,381 | 4,037 | 4,501 | 4,775 | 4,971 | 4,798 | 5,046 | 5,226 | 4,498 | 4,210 |
| Expenses | 3,025 | 3,209 | 3,141 | 3,337 | 3,309 | 3,479 | 3,422 | 3,703 | 3,777 | 3,643 |
| Operating Profit | 1,356 | 828 | 1,360 | 1,438 | 1,662 | 1,319 | 1,624 | 1,523 | 721 | 567 |
| OPM % | 31% | 21% | 30% | 30% | 33% | 27% | 32% | 29% | 16% | 13% |
| Net Profit | 1,114 | 1,038 | 1,056 | 1,178 | 1,438 | 1,485 | 1,303 | 1,211 | 617 | 385 |
| EPS ₹ | 13.8 | 12.86 | 13.08 | 14.59 | 17.81 | 18.39 | 16.13 | 14.99 | 7.64 | 4.76 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹18,980Cr, down 0.3% YoY. OPM at 23%.
Debt Position
Borrowings at ₹125Cr. Debt-to-equity ratio: 0.00x. Healthy balance sheet.
Capex Cycle
CWIP at ₹720Cr (13% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 31.71% (+7.66pp change). FIIs: 22.55% (-2.94pp change). Promoters hold 29.22%.
Margin & Efficiency
ROCE improving from 14% (Mar 2015) to 15% (Mar 2026). Working capital days: 260.
Valuation
PE 31.3x with 14.7% ROCE. Price is 239% above book value of ₹423. Dividend yield: 0.92%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 2d - We are enclosing hereby a copy of transcript of the Company''s Q4 FY26 earnings conference call dated 13th May, 2026
- Announcement under Regulation 30 (LODR)-Newspaper Publication 14 May
- Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 14 May - The Operations and Administrative Committee of the company on 14th May, 2026 has allotted 17,915 fully paid-up equity shares of INR 2 each, pursuant to …
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 13 May - Audio recording of Cipla’s Q4 and FY2026 earnings conference call is now available on its website.
- Grant Of Stock Options And The Employee Stock Appreciation Rights 13 May - Cipla approved 25 June 2026 AGM, ESOP/ESAR grants, FY27 cost auditor, and Sushrut Kulkarni appointment.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse